News & Updates
Filter by Specialty:
Circulating antioxidants play no protective role in breast, ovarian cancers
Genetically predicted circulating antioxidants do not appear to have a protective effect on the risk of breast cancer, ovarian cancer, or their histotypes, according to the results of a two-sample Mendelian randomization study.
Circulating antioxidants play no protective role in breast, ovarian cancers
23 Apr 2022
Furmonertinib emerges as potential first-line option for EGFRm NSCLC
Treatment-naïve patients with locally advanced or metastatic EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) experience improved progression-free survival (PFS) when treated with furmonertinib compared with gefitinib, according to results of the phase III FURLONG study.
Furmonertinib emerges as potential first-line option for EGFRm NSCLC
22 Apr 2022
Ritlecitinib, brepocitinib show promise against scalp alopecia areata
Ritlecitinib and brepocitinib lead to improvements in scalp alopecia areata and its associated biomarkers, reveals a recent substudy of a phase 2a trial.
Ritlecitinib, brepocitinib show promise against scalp alopecia areata
22 Apr 2022
Larger tumours tied to prostate cancer biochemical recurrence
In patients with localized prostate cancer (PCa), higher tumour volume (TV) appears to cut biochemical recurrence-free survival short, a recent study has found.
Larger tumours tied to prostate cancer biochemical recurrence
22 Apr 2022
Does reducing salt intake impact CV outcomes?
An intervention aimed at reducing sodium intake in patients with heart failure (HF) does not reduce the risk of emergency department (ED) presentation or hospitalization for cardiovascular (CV) causes or all-cause death, according to results of the SODIUM-HF* trial. However, patients did experience improvements in quality of life (QoL) and New York Heart Association (NYHA) class.